Safety and Acceptability of a Vaginal Microbicide - Related Studies

Safety and Acceptability of a Vaginal Microbicide

This study has been completed.

Study NCT00111943. Last updated on September 26, 2008. Information provided by National Institute of Allergy and Infectious Diseases (NIAID)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		HIV Infections
		Hepatitis B, Chronic

2	Additional conditions recognized in this trial
		Acquired Immunodeficiency Syndrome
		Hepatitis
		Hepatitis B
		Infection

3	More general conditions related to this trial
		Digestive System Diseases
		DNA Virus Infections
		Hepadnaviridae Infections
		Hepatitis, Chronic
		Hepatitis, Viral, Human
		Immune System Diseases
		Immunologic Deficiency Syndromes
		Lentivirus Infections
		Liver Diseases
		Retroviridae Infections
		RNA Virus Infections
		Sexually Transmitted Diseases
		Sexually Transmitted Diseases, Viral
		Slow Virus Diseases
		Virus Diseases

4	Interventions listed in this trial
		1% tenofovir gel

5	Additional drug interventions recognized in this trial
		Tenofovir
		Tenofovir disoproxil

6	More general drug interventions related to this trial
		Anti-HIV Agents
		Anti-Infective Agents
		Anti-Retroviral Agents
		Antiviral Agents
		Enzyme Inhibitors
		Molecular Mechanisms of Pharmacological Action
		Nucleic Acid Synthesis Inhibitors
		Pharmacologic Actions
		Reverse Transcriptase Inhibitors
		Therapeutic Uses

7	Sponsors listed in this trial
		National Institute of Allergy and Infectious Diseases (NIAID)
		Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
		National Institute on Drug Abuse (NIDA)
		National Institute of Mental Health (NIMH)